Tumours carry different combinations of genetic mutations in each patient. Prompting the immune system to recognise protein fragments arising from those differences is the basic principle.

A relative advantage of the mRNA approach is the short interval from design to manufacture, which matters especially where every preparation must differ by patient.

Manufacturing throughput, cold-chain storage in distribution and cost remain open problems. Moving clinical results into routine practice takes time.

Management of immune-related side effects is examined alongside. The more strongly a treatment provokes an immune response, the more important monitoring becomes.

Research stages and approval stages should be read separately. Early results do not make a therapy standard of care.

In an ageing society, changes in cancer treatment connect to the structure of health spending, and assessments weighing effect against cost are expected to follow.